OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Subscription and Copyright Information	850
Shearing of surface mucin saps tumor cell strength	541
Subscription and Copyright Information	395
Structural asymmetry in FGF23 signaling	219
Advisory Board and Contents	214
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	195
Subscription and Copyright Information	182
Subscription and Copyright Information	164
Muscarinic receptors: from clinic to bench to clinic	153
Subscription and Copyright Information	150
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	146
Peptides as a therapeutic strategy against Klebsiella pneumoniae	139
Compstatins: the dawn of clinical C3-targeted complement inhibition	121
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	121
Swinging the SWI/SNF complexes for cancer therapy	121
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	116
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	111
Targeting complement in neurodegeneration: challenges, risks, and strategies	106
Therapeutic inhibition of ferroptosis in neurodegenerative disease	105
Structural pharmacology and mechanisms of GLP-1R signaling	105
Direct in vivo CAR T cell engineering	94
Advisory Board and Contents	86
Nemolizumab (Nemluvio®) for prurigo nodularis	86
Ribosome-directed cancer therapies: the tip of the iceberg?	85
Phenotypic approaches for CNS drugs	84

A deep dive into degrader-induced protein-protein interfaces	80
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	79
Advisory Board and Contents	78
A perspective on psychedelic teratogenicity: the utility of zebrafish models	77
Advisory Board and Contents	76
Optogenetic engineering for precision cancer immunotherapy	70
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	69
A smart hospital-driven approach to precision pharmacovigilance	69
Leveraging human microbiomes for disease prediction and treatment	68
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	68
siRNA drug Leqvio (inclisiran) to lower cholesterol	67
HSV-1 as a gene delivery platform for cancer gene therapy	66
Engineering ACE2 decoy receptors to combat viral escapability	64
Close to a year in TIPS’ saddle – I am optimistic	64
Genetically engineered loaded extracellular vesicles for drug delivery	64
Emerging strategies for beta cell transplantation to treat diabetes	64
Subscription and Copyright Information	61
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	58
Thriving as members of under-represented groups in pharmacology-related careers	56
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	55
Advisory Board and Contents	54
Bimetallic nanoadjuvants for cancer vaccines	54
Subscription and Copyright Information	53
Lipoxygenases in chronic liver diseases: current insights and future perspectives	53
Suzetrigine for moderate to severe acute pain	52
Could dexmedetomidine be repurposed as a glymphatic enhancer?	51
Mentoring future science leaders to thrive	47
Now you serine, now you don't	46
Emerging approaches to induce immune tolerance to therapeutic proteins	45
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	45
Piezo1: structural pharmacology and mechanotransduction mechanisms	45
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	44
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	44
Advancing non-destructive analysis of 3D printed medicines	42
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	41
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	41
The structure, function, and pharmacology of MRGPRs	41
The road less traveled: activating an oncogenic kinase	40
Advisory Board and Contents	40
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
The promise of targeted protein degradation approaches	38
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	38
Salt-inducible kinases: new players in pulmonary arterial hypertension?	38
Promising neuroimmune targets and drugs for CNS diseases	37
A novel function of the M2 muscarinic receptor	37
Subscription and Copyright Information	36
The end of the beginning in understanding SLC22 polyspecificity	36
Advisory Board and Contents	35
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	35
Validation of agent-based models of surface receptor oligomerisation	35

Frizzleds act as dynamic pharmacological entities	34
Targeting intracellular protein–protein interactions with macrocyclic peptides	33
Protein acylations in cancer immunity: effects and therapeutic opportunities	33
Monkeypox: potential vaccine development strategies	33
Nanocarriers for oral delivery of biologics: small carriers for big payloads	33
Tackling microbial iron homeostasis: novel antimicrobial strategies	33
Decoding pseudouridine: an emerging target for therapeutic development	33
BTK inhibitors: past, present, and future	32
Advisory Board and Contents	32
Metabolic regulation in normal and leukemic stem cells	32
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	31
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	31
Demographic diversity in platelet function and response to antiplatelet therapy	31
Circulating tumor cells in precision medicine: challenges and opportunities	31
Development of PROTACs using computational approaches	30
Subscription and Copyright Information	29
Recent advances in generative biology for biotherapeutic discovery	29
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	29
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
Eflornithine for treatment of high-risk neuroblastoma	28
Engineered antibody fusion proteins for targeted disease therapy	28
GPR35: from enigma to therapeutic target	28
Biologics and cardiac disease: challenges and opportunities	27
Subscription and Copyright Information	27
Targeting plasma membrane cholesterol as a novel anticancer therapy	27
Targeting sensory neuron GPCRs for peripheral neuropathic pain	27
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	27
Subscription and Copyright Information	27
A novel anticancer pharmacological agent targeting mitochondrial complex I	25
Tackling chronic kidney disease in diabetic patients with finerenone	25
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	25
High-power screening (HPS) empowered by DNA-encoded libraries	25
Subscription and Copyright Information	25
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	24
Harnessing associative learning paradigms to optimize drug treatment	24
Boosting CAR-T cell therapy through vaccine synergy	24
Subscription and Copyright Information	23
Neutrophil extracellular traps in wound healing	23
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	23
Visceral obesity and HFpEF: targets and therapeutic opportunities	23
Recent advancements in vaccine research and development	23
The ABCs of psychedelics: a preclinical roadmap for drug discovery	22
Challenges and opportunities associated with rare-variant pharmacogenomics	22
Taming PRMT5–adaptor protein interactions	22
Circadian biology to advance therapeutics for mood disorders	22
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	21
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	21
Advisory Board and Contents	20
NLRP3 and pyroptosis blockers for treating inflammatory diseases	20
Potential for targeting small heat shock protein modifications	20
GPCR-dependent and -independent arrestin signaling	20
GABAA receptors as targets for treating affective and cognitive symptoms of depression	20
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Subscription and Copyright Information	19
Odorant receptors as potential drug targets	19
The structure and function of YTHDF epitranscriptomic m6A readers	18
Subscription and Copyright Information	18
Glymphatic-stagnated edema induced by traumatic brain injury	18
Advisory Board and Contents	18
Malolactone strikes: K-Ras-G12D's Achilles' heel	18
Targeted protein degrader development for cancer: advances, challenges, and opportunities	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
Hans Jürg Schatzmann (1924–2021)	17
Advisory Board and Contents	17
Bridging the gap in neuropsychiatric translational research	17
Glaucoma: neuroprotection with NAD-based therapeutic interventions	17
Learning from natural design for local anesthetic delivery	17
Advancing small-molecule drug discovery by encoded dual-display technologies	17